Medicines made by compounding pharmacies dont undergo the same scrutiny as those made in SAHPRA-approved factories, and pose multiple risks to patients, including dosing errors and contamination, she said
View abstract.
Based on the February 2026 HHS announcement and analysis from compounding pharmacy and regulatory experts, the peptides expected to return to Category 1 status include BPC-157, Thymosin Alpha-1, TB-500, CJC-1295, Ipamorelin, AOD-9604, GHK-Cu, Selank, Semax, KPV, MOTS-C, and several others approximately 14 of the original 19 restricted compounds
The FDA resolved its designation of a semaglutide shortage in February 2025, which directly affected the regulatory framework around compounding of GLP-1 products